Diagnostic performance of microcytic anemia factor in the evaluation of functional iron deficiency in diabetic kidney disease

Aro P.; Lezama C.; Solano D.; Castillo J.; Sánchez Jacinto B.; Paredes R.; Acosta M.; Manrique H. · Revista de la Sociedad Argentina de Diabetes (2024) · DOI: 10.47196/diab.v58i3.1141

Resumen

Introduction: measurement of microcytic anemia factor (Maf®) is rapid and cost-effective. Studies demonstrate its usefulness in the study of iron metabolism, however its performance in the diagnosis of functional iron deficiency (FID) is limited. Objectives: to evaluate the diagnostic performance of Maf® and to establish the cut-off point for early detection of DHF in diabetic kidney disease (DKD). Materials and methods: cross-sectional study. We included 160 people with a diagnosis of DKD who attended the Diabetes, Obesity and Nutrition Research Center (CIDON) in Lima (Peru) during 2022-2023. A reticulocyte hemoglobin equivalent (RetHe) value <29 pg was established as a diagnostic criterion for FID. The Maf® was calculated by the formula: Maf® = ([Hb x VCM] /100). The receiver operating characteristic curve (ROC) with the area under the curve (AUC) was used to predict FID. Results: the frequency of FID was 89.4%. A statistically significant relationship was found between Maf® and FID (p=0.005). ROC curve analysis for Maf® showed an AUC of 0.706 (p=0.001) with a cutoff point of 10.85 (sensitivity 70.59% and specificity of 69.93%) for the detection of DHF in people with DKD. Conclusions: Maf® has a moderate performance in the identification of FID and could be a potential tool in the screening of patients with DKD.

Instituciones: Universidad Peruana Cayetano Heredia